View in EDS

Preparation of particle-attached microneedles using a dry coating process.

Saved in:
Bibliographic Details
Title: Preparation of particle-attached microneedles using a dry coating process.
Authors: Choi, Jeong-Eun1 (AUTHOR), Cha, Hye-Ran1,2 (AUTHOR), Kim, Suwan1 (AUTHOR), Kim, Ji Seok3 (AUTHOR), Kim, Mun-Jin1 (AUTHOR), Chung, Hyeon Woo2 (AUTHOR), Baek, Seung-Ki3 (AUTHOR), Lee, Jae Myun1,2 (AUTHOR) jaemyun@yuhs.ac, Park, Jung-Hwan1 (AUTHOR) pa90201@gachon.ac.kr
Source: Journal of Controlled Release. Nov2022, Vol. 351, p1003-1016. 14p.
Subjects: Polylactic acid, Coating processes, Manufacturing processes, Antibody titer, Ovum, Polydimethylsiloxane, Titers
Abstract: The standard process for manufacturing microneedles containing API requires a way to process the API, including dissolving the API in a co-solvent and a drying process. In this study, the authors introduce a novel microneedle system that involves physically attaching API particles to the biocompatible adhesive surface of the microneedles. To manufacture particle-attached microneedles, an adhesive surface was prepared by coating polydimethylsiloxane (PDMS) mixed with an elastomer base and a curing agent at a ratio of 40:1 (PDMS40) onto polylactic acid microneedles (PLA), and then attaching ovalbumin (OVA) particles with a mean diameter of 10 μm to the PDMS adhesive layer. The OVA particles were delivered for 5 min into porcine skin with a delivery efficiency of 93% ex vivo and into mouse skin with a delivery efficiency of over 90% in vivo. Finally, mouse experiments with OVA particle-attached microneedles showed a value of OVA antibody titer similar to that produced by intramuscular administration. Particle-attached microneedles are a novel microneedle system with a dry coating process and rapid API delivery into the skin. Particle-attached microneedles can provide a wide range of applications for administering drugs and vaccines. [Display omitted] [ABSTRACT FROM AUTHOR]
Copyright of Journal of Controlled Release is the property of Elsevier B.V. and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Engineering Source
Description
Abstract:The standard process for manufacturing microneedles containing API requires a way to process the API, including dissolving the API in a co-solvent and a drying process. In this study, the authors introduce a novel microneedle system that involves physically attaching API particles to the biocompatible adhesive surface of the microneedles. To manufacture particle-attached microneedles, an adhesive surface was prepared by coating polydimethylsiloxane (PDMS) mixed with an elastomer base and a curing agent at a ratio of 40:1 (PDMS40) onto polylactic acid microneedles (PLA), and then attaching ovalbumin (OVA) particles with a mean diameter of 10 μm to the PDMS adhesive layer. The OVA particles were delivered for 5 min into porcine skin with a delivery efficiency of 93% ex vivo and into mouse skin with a delivery efficiency of over 90% in vivo. Finally, mouse experiments with OVA particle-attached microneedles showed a value of OVA antibody titer similar to that produced by intramuscular administration. Particle-attached microneedles are a novel microneedle system with a dry coating process and rapid API delivery into the skin. Particle-attached microneedles can provide a wide range of applications for administering drugs and vaccines. [Display omitted] [ABSTRACT FROM AUTHOR]
ISSN:01683659
DOI:10.1016/j.jconrel.2022.10.003